Advanced Heart Failure Therapies in Neuromuscular Diseases
Arianne Clare Agdamag1, Phoo Pwint Nandar2, W H Wilson Tang1
1Section of Advanced Heart Failure and Transplantation Medicine, Department of Cardiovascular Medicine, Miller Family Heart, Vascular and Thoracic Institute, Robert and Suzanne Tomsich, Cleveland Clinic, Cleveland, OH 44195, USA.
Current Treatment Options in Cardiovascular Medicine
|January 8, 2025
Summary
Heart failure is the leading cause of death in patients with neuromuscular disorders. Advanced therapies like ventricular assist devices and heart transplantation offer feasible and safe options for selected individuals.
Area of Science:
- Cardiology
- Neurology
- Transplantation Science
Background:
- Neuromuscular disorders frequently involve multisystemic complications, notably cardiovascular pathology.
- Heart failure has emerged as the primary cause of mortality in this population due to improved management of respiratory issues.
- Advanced heart failure therapies are increasingly recognized as viable options.
Purpose of the Study:
- To review the prevalence of advanced heart failure therapies in patients with neuromuscular disorders.
- To examine the utilization patterns of these therapies.
- To assess the outcomes associated with advanced heart failure treatments in this cohort.
Main Methods:
- This is a review article.
- Literature search on advanced heart failure therapies in neuromuscular disorders.
- Analysis of prevalence, utilization, and outcomes data.
Main Results:
- Advanced heart failure therapies, including durable left ventricular assist devices and heart transplantation, are feasible and safe in selected patients.
- Early recognition and multidisciplinary management are crucial for successful outcomes.
- Heart failure is the leading cause of mortality in patients with neuromuscular disorders.
Conclusions:
- Multidisciplinary management is essential for patients with neuromuscular disorders and heart failure.
- Timely initiation of advanced heart failure therapies can lead to successful outcomes.
- Selected patients with neuromuscular disorders can benefit from advanced heart failure interventions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:26Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K